company logo
About ReViral

ReViral has a founding team of experienced executives, managers and scientists who work closely with key collaborators and consultants by combining expertise in the areas of virology and antiviral therapies that facilitate the prosecution of the company's key research and development programs

  • ReViral was founded in 2011 by a number of members of the highly successful Arrow Therapeutics team, led by Dr Ken Powell as CEO and Dr Stuart Cockerill as CSO
  • The team has a track record in the development of compounds with activity against RSV

  • After initial seed funding in 2013 ReViral won a prestigious Seeding Drug Discovery award enabling the development of its novel fusion inhibitors of RSV

  • Professor Raymond Schinazi joined the ReViral board in 2014, and the company also enlisted the help of Max Herrmann as its CFO

  • In 2015 ReViral announced US$21 million fundraising to advance clinical development of a novel anti-viral drug

  • Dr Rachel Harland joined ReViral in 2015 as COO with responsibility for the development of ReViral’s RSV programmes

  • In 2016 ReViral established laboratory facilities at the Stevenage BioSciences Park and North East Technology Park

  • In October 2016 ReViral announced the recruitment of Dr Eddy Littler as Chief Executive Officer